Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results U.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Collaboration with Eli Lilly and...

Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3 BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...

National Lipid Association Releases Official Scientific Statement Regarding Use of Lipoprotein(a) in Clinical Practice JACKSONVILLE, Fla., May 17, 2019 (GLOBE NEWSWIRE) -- The National Lipid Association (NLA) today announced the release of an official scientific statement on Lipoprotein(a) [Lp(a)] clinical use at...

PCSK9 Barriers Survey Results Revealed at National Lipid Association Conference PHOENIX, AZ--(Marketwired - February 07, 2017) - As part of its Spring Clinical Lipid Update (CLU) in Phoenix, the National Lipid Association (NLA) will reveal the results of its "Challenges in...